Blake Mandell

Transcend Therapeutics is an American biotechnology company that discovers, develops, and delivers next-generation psychoactive medicines to work towards a world where people no longer suffer from neuropsychiatric disease. The company is located in the US. The company focuses on developing medicines that are accessible to a larger percentage of patients in need, specifically the tens of millions of patients who already take psychotropic medication. Transcend Therapeutics has real-world data for its lead compound, TSND-201, demonstrating robust responses in patients with PTSD. As a public benefit corporation, the company has pledged 10% of its founding shares towards nonprofits focused on scientific research and patient access.

Transcend Therapeutics is an American biotechnology company that discovers, develops, and delivers next-generation psychoactive medicines to work towards a world where people no longer suffer from neuropsychiatric disease. The company is located in the US. The company focuses on developing medicines that are accessible to a larger percentage of patients in need, specifically the tens of millions of patients who already take psychotropic medication. Transcend Therapeutics has real-world data for its lead compound, TSND-201, demonstrating robust responses in patients with PTSD. As a public benefit corporation, the company has pledged 10% of its founding shares towards nonprofits focused on scientific research and patient access.

Transcend Therapeutics is an American biotechnology company that discovers, develops, and delivers next-generation psychoactive medicines to work towards a world where people no longer suffer from neuropsychiatric disease. The company is located in the US. The company focuses on developing medicines that are accessible to a larger percentage of patients in need, specifically the tens of millions of patients who already take psychotropic medication. Transcend Therapeutics has real-world data for its lead compound, TSND-201, demonstrating robust responses in patients with PTSD. As a public benefit corporation, the company has pledged 10% of its founding shares towards nonprofits focused on scientific research and patient access.

Transcend Therapeutics is an American biotechnology company that discovers, develops, and delivers next-generation psychoactive medicines to work towards a world where people no longer suffer from neuropsychiatric disease. The company is located in the US. The company focuses on developing medicines that are accessible to a larger percentage of patients in need, specifically the tens of millions of patients who already take psychotropic medication. Transcend Therapeutics has real-world data for its lead compound, TSND-201, demonstrating robust responses in patients with PTSD. As a public benefit corporation, the company has pledged 10% of its founding shares towards nonprofits focused on scientific research and patient access.